Symbols / ACIU
ACIU Chart
About
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 273.63M |
| Enterprise Value | 170.62M | Income | -71.87M | Sales | 4.37M |
| Book/sh | 0.80 | Cash/sh | 1.07 | Dividend Yield | — |
| Payout | 0.00% | Employees | 133 | IPO | — |
| P/E | — | Forward P/E | -3.69 | PEG | — |
| P/S | 62.59 | P/B | 3.40 | P/C | — |
| EV/EBITDA | -2.38 | EV/Sales | 39.03 | Quick Ratio | 1.12 |
| Current Ratio | 1.16 | Debt/Eq | 7.46 | LT Debt/Eq | — |
| EPS (ttm) | -0.93 | EPS next Y | -0.74 | EPS Growth | — |
| Revenue Growth | -96.30% | Earnings | 2026-03-12 | ROA | -21.96% |
| ROE | -74.63% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -16.72% | Profit Margin | 0.00% | Shs Outstand | 100.60M |
| Shs Float | 40.07M | Short Float | 6.92% | Short Ratio | 8.25 |
| Short Interest | — | 52W High | 4.00 | 52W Low | 1.43 |
| Beta | 1.62 | Avg Volume | 719.59K | Volume | 233.49K |
| Target Price | $9.17 | Recom | Strong_buy | Prev Close | $2.53 |
| Price | $2.72 | Change | 7.51% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.17
Mean price target
2. Current target
$2.72
Latest analyst target
3. DCF / Fair value
$-3.30
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.72
Low
$7.00
High
$12.48
Mean
$9.17
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-04 | reit | BTIG | Buy → Buy | $8 |
| 2025-09-08 | reit | BTIG | Buy → Buy | $8 |
| 2025-05-01 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2025-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-11-06 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-09-18 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2024-05-31 | init | BTIG | — → Buy | $8 |
| 2024-03-15 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2023-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2023-08-07 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2023-06-28 | reit | HC Wainwright & Co. | Buy → Buy | $16 |
| 2023-05-01 | reit | HC Wainwright & Co. | — → Buy | $16 |
| 2023-04-19 | reit | HC Wainwright & Co. | — → Buy | $16 |
| 2023-03-17 | reit | HC Wainwright & Co. | — → Buy | $16 |
| 2022-07-11 | main | SVB Leerink | — → Outperform | $10 |
| 2021-12-20 | main | SVB Leerink | — → Outperform | $15 |
| 2021-03-24 | main | HC Wainwright & Co. | — → Buy | $16 |
| 2019-12-10 | reit | HC Wainwright & Co. | — → Buy | $11 |
- First tests for AC Immune pill targeting brain inflammation in Alzheimer’s - Stock Titan ue, 24 Feb 2026 12
- AC Immune SA's (NASDAQ:ACIU) stock price dropped 11% last week; retail investors would not be happy - simplywall.st Wed, 10 Dec 2025 08
- Does ACIU stock have upside surprise potential - 2025 Price Momentum & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn Wed, 25 Feb 2026 00
- AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance ue, 04 Nov 2025 08
- AC Immune surges on positive mid-stage trial data for Parkinson’s drug - Seeking Alpha hu, 11 Dec 2025 08
- How ACIU stock valuations compare to rivals - July 2025 Weekly Recap & Weekly Watchlist of Top Performers - mfd.ru Fri, 20 Feb 2026 14
- ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? - Nasdaq Mon, 24 Mar 2025 07
- AC Immune stock rises after positive Parkinson’s disease trial data - Investing.com hu, 11 Dec 2025 08
- Why Is AC Immune Stock Up Over 23% Today? - Stocktwits hu, 11 Dec 2025 08
- AC Immune SA Announces Strategic Pipeline Focus and Workforce Reduction to Extend Cash Runway - Quiver Quantitative hu, 04 Sep 2025 07
- Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline - Yahoo Finance ue, 28 Oct 2025 07
- AC Immune (NASDAQ: ACIU) Phase 2 data show stabilized markers in Parkinson’s - Stock Titan hu, 11 Dec 2025 08
- AC Immune SA (NASDAQ:ACIU) Held Back By Insufficient Growth Even After Shares Climb 31% - simplywall.st Wed, 11 Jun 2025 07
- AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD - Seeking Alpha Mon, 15 Dec 2025 08
- AC Immune (NASDAQ: ACIU) schedules Nov 18 fireside chat at 9:30 AM GMT; webcast - Stock Titan ue, 11 Nov 2025 08
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -135.83K | -124.69K | 51.09K | 3.39K |
| TaxRateForCalcs | 0.09 | 0.09 | 0.13 | 0.03 |
| NormalizedEBITDA | -47.02M | -50.37M | -68.42M | -70.12M |
| TotalUnusualItems | -1.60M | -1.47M | 393.00K | 113.00K |
| TotalUnusualItemsExcludingGoodwill | -1.60M | -1.47M | 393.00K | 113.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -50.92M | -54.23M | -70.75M | -73.00M |
| ReconciledDepreciation | 2.16M | 2.21M | 2.36M | 2.41M |
| EBITDA | -48.62M | -51.83M | -68.03M | -70.01M |
| EBIT | -50.78M | -54.05M | -70.39M | -72.41M |
| NetInterestIncome | 3.06M | 868.00K | -286.00K | 5.90M |
| InterestExpense | 133.00K | 176.00K | 355.00K | 581.00K |
| InterestIncome | 3.20M | 1.04M | 69.00K | 6.49M |
| NormalizedIncome | -49.45M | -52.89M | -71.09M | -73.11M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -50.92M | -54.23M | -70.75M | -73.00M |
| TotalExpenses | 79.69M | 68.42M | 74.78M | 79.01M |
| TotalOperatingIncomeAsReported | -52.38M | -53.62M | -70.85M | -79.01M |
| DilutedAverageShares | 99.84M | 84.69M | 83.55M | 74.95M |
| BasicAverageShares | 99.84M | 84.69M | 83.55M | 74.95M |
| DilutedEPS | -0.51 | -0.64 | -0.85 | -0.97 |
| BasicEPS | -0.51 | -0.64 | -0.85 | -0.97 |
| DilutedNIAvailtoComStockholders | -50.92M | -54.23M | -70.75M | -73.00M |
| NetIncomeCommonStockholders | -50.92M | -54.23M | -70.75M | -73.00M |
| NetIncome | -50.92M | -54.23M | -70.75M | -73.00M |
| NetIncomeIncludingNoncontrollingInterests | -50.92M | -54.23M | -70.75M | -73.00M |
| NetIncomeContinuousOperations | -50.92M | -54.23M | -70.75M | -73.00M |
| TaxProvision | 3.00K | 10.00K | 13.00K | 3.00K |
| PretaxIncome | -50.91M | -54.22M | -70.74M | -72.99M |
| OtherIncomeExpense | -1.60M | -1.47M | 393.00K | 113.00K |
| GainOnSaleOfSecurity | -1.60M | -1.47M | 393.00K | 113.00K |
| NetNonOperatingInterestIncomeExpense | 3.06M | 868.00K | -286.00K | 5.90M |
| InterestExpenseNonOperating | 133.00K | 176.00K | 355.00K | 581.00K |
| InterestIncomeNonOperating | 3.20M | 1.04M | 69.00K | 6.49M |
| OperatingIncome | -52.38M | -53.62M | -70.85M | -79.01M |
| OperatingExpense | 79.69M | 68.42M | 74.78M | 79.01M |
| OtherOperatingExpenses | 5.68M | 3.24M | 4.86M | 5.85M |
| ResearchAndDevelopment | 62.57M | 54.61M | 60.34M | 62.28M |
| SellingGeneralAndAdministration | 11.43M | 10.58M | 9.58M | 10.88M |
| GeneralAndAdministrativeExpense | 11.43M | 10.58M | 9.58M | 10.88M |
| SalariesAndWages | 11.43M | 10.58M | 9.58M | 10.88M |
| TotalRevenue | 27.31M | 14.80M | 3.94M | 0.00 |
| OperatingRevenue | 27.31M | 14.80M | 3.94M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 10.90M | 5.24M | 6.21M | 6.22M |
| OrdinarySharesNumber | 100.41M | 99.20M | 83.62M | 83.48M |
| ShareIssued | 111.31M | 104.44M | 89.83M | 89.70M |
| TotalDebt | 5.43M | 3.50M | 2.80M | 2.91M |
| TangibleBookValue | 61.85M | 110.23M | 118.58M | 181.56M |
| InvestedCapital | 112.27M | 160.64M | 168.99M | 231.98M |
| WorkingCapital | 71.16M | 111.58M | 116.61M | 182.61M |
| NetTangibleAssets | 61.85M | 110.23M | 118.58M | 181.56M |
| CapitalLeaseObligations | 5.43M | 3.50M | 2.80M | 2.91M |
| CommonStockEquity | 112.27M | 160.64M | 168.99M | 231.98M |
| TotalCapitalization | 112.27M | 160.64M | 168.99M | 231.98M |
| TotalEquityGrossMinorityInterest | 112.27M | 160.64M | 168.99M | 231.98M |
| StockholdersEquity | 112.27M | 160.64M | 168.99M | 231.98M |
| GainsLossesNotAffectingRetainedEarnings | -5.00K | -51.00K | 10.00K | 0.00 |
| ForeignCurrencyTranslationAdjustments | -5.00K | -51.00K | 10.00K | 0.00 |
| TreasuryStock | 218.00K | 105.00K | 124.00K | 124.00K |
| RetainedEarnings | -368.24M | -316.20M | -264.01M | -200.94M |
| AdditionalPaidInCapital | 478.51M | 474.91M | 431.32M | 431.25M |
| CapitalStock | 2.23M | 2.09M | 1.80M | 1.79M |
| CommonStock | 2.23M | 2.09M | 1.80M | 1.79M |
| TotalLiabilitiesNetMinorityInterest | 118.64M | 22.17M | 16.95M | 29.46M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 17.80M | 8.60M | 5.47M | 9.44M |
| EmployeeBenefits | 8.84M | 5.77M | 3.21M | 7.10M |
| NonCurrentDeferredLiabilities | 4.56M | 0.00 | ||
| NonCurrentDeferredRevenue | 4.56M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 4.40M | 2.83M | 2.25M | 2.34M |
| LongTermCapitalLeaseObligation | 4.40M | 2.83M | 2.25M | 2.34M |
| CurrentLiabilities | 100.84M | 13.58M | 11.48M | 20.03M |
| CurrentDeferredLiabilities | 85.06M | 138.00K | 587.00K | 717.00K |
| CurrentDeferredRevenue | 85.06M | 138.00K | 587.00K | 717.00K |
| CurrentDebtAndCapitalLeaseObligation | 1.03M | 672.00K | 548.00K | 570.00K |
| CurrentCapitalLeaseObligation | 1.03M | 672.00K | 548.00K | 570.00K |
| PayablesAndAccruedExpenses | 14.76M | 12.77M | 10.35M | 18.74M |
| CurrentAccruedExpenses | 12.10M | 11.09M | 9.42M | 16.74M |
| Payables | 2.66M | 1.68M | 929.00K | 2.00M |
| AccountsPayable | 2.66M | 1.68M | 929.00K | 2.00M |
| TotalAssets | 230.91M | 182.81M | 185.94M | 261.44M |
| TotalNonCurrentAssets | 58.92M | 57.66M | 57.84M | 58.81M |
| InvestmentsAndAdvances | 415.00K | 361.00K | 361.00K | 363.00K |
| InvestmentinFinancialAssets | 415.00K | 361.00K | 361.00K | 363.00K |
| GoodwillAndOtherIntangibleAssets | 50.42M | 50.42M | 50.42M | 50.42M |
| OtherIntangibleAssets | 50.42M | 50.42M | 50.42M | 50.42M |
| NetPPE | 8.09M | 6.88M | 7.07M | 8.03M |
| AccumulatedDepreciation | -12.47M | -11.00M | -9.34M | -7.55M |
| GrossPPE | 20.56M | 17.88M | 16.41M | 15.58M |
| Leases | 1.86M | 1.66M | 1.64M | 810.00K |
| ConstructionInProgress | 0.00 | 0.00 | 3.00K | 695.00K |
| OtherProperties | 10.54M | 10.23M | 9.77M | 9.14M |
| MachineryFurnitureEquipment | 2.84M | 2.54M | 2.29M | 2.16M |
| BuildingsAndImprovements | 5.32M | 3.45M | 2.71M | 2.78M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 171.99M | 125.15M | 128.09M | 202.63M |
| PrepaidAssets | 4.30M | 6.44M | 4.71M | 3.02M |
| Receivables | 2.20M | 15.67M | 800.00K | 1.40M |
| OtherReceivables | 1.24M | 291.00K | 532.00K | 1.08M |
| TaxesReceivable | 960.00K | 577.00K | 268.00K | 327.00K |
| AccountsReceivable | 0.00 | 14.80M | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 165.49M | 103.05M | 122.59M | 198.22M |
| OtherShortTermInvestments | 129.21M | 24.55M | 91.00M | 116.00M |
| CashAndCashEquivalents | 36.27M | 78.49M | 31.59M | 82.22M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 65.27M | -61.21M | -74.81M | -68.32M |
| RepurchaseOfCapitalStock | -8.00K | 0.00 | ||
| RepaymentOfDebt | -683.00K | -548.00K | -569.00K | -513.00K |
| IssuanceOfDebt | 0.00 | 0.00 | 23.46M | |
| IssuanceOfCapitalStock | 111.00K | 43.80M | 7.00K | 17.80M |
| CapitalExpenditure | -576.00K | -801.00K | -1.24M | -2.63M |
| EndCashPosition | 36.27M | 78.49M | 31.59M | 82.22M |
| BeginningCashPosition | 78.49M | 31.59M | 82.22M | 160.89M |
| EffectOfExchangeRateChanges | -1.65M | -1.58M | 521.00K | -70.00K |
| ChangesInCash | -40.57M | 48.49M | -51.15M | -78.61M |
| FinancingCashFlow | -1.12M | 43.25M | -1.35M | 40.75M |
| CashFlowFromContinuingFinancingActivities | -1.12M | 43.25M | -1.35M | 40.75M |
| NetOtherFinancingCharges | -548.00K | -776.00K | -6.00K | |
| ProceedsFromStockOptionExercised | 7.00K | 1.08M | ||
| NetCommonStockIssuance | 111.00K | 43.80M | -1.00K | 17.80M |
| CommonStockPayments | -8.00K | 0.00 | ||
| CommonStockIssuance | 111.00K | 43.80M | 7.00K | 17.80M |
| NetIssuancePaymentsOfDebt | -683.00K | -548.00K | -569.00K | 22.95M |
| NetShortTermDebtIssuance | 0.00 | 0.00 | ||
| ShortTermDebtPayments | 0.00 | 0.00 | ||
| NetLongTermDebtIssuance | -683.00K | -548.00K | -569.00K | 22.95M |
| LongTermDebtPayments | -683.00K | -548.00K | -569.00K | -513.00K |
| LongTermDebtIssuance | 0.00 | 0.00 | 23.46M | |
| InvestingCashFlow | -105.29M | 65.64M | 23.76M | -53.66M |
| CashFlowFromContinuingInvestingActivities | -105.29M | 65.64M | 23.76M | -53.66M |
| NetOtherInvestingChanges | -54.00K | 2.00K | -29.00K | |
| NetInvestmentPurchaseAndSale | -104.66M | 66.45M | 25.00M | -51.00M |
| NetPPEPurchaseAndSale | -576.00K | -801.00K | -1.24M | -2.63M |
| SaleOfPPE | 0.00 | 0.00 | ||
| PurchaseOfPPE | -576.00K | -801.00K | -1.24M | -2.63M |
| OperatingCashFlow | 65.84M | -60.41M | -73.57M | -65.69M |
| CashFlowFromContinuingOperatingActivities | 65.84M | -60.41M | -73.57M | -65.69M |
| InterestReceivedCFO | 1.56M | 595.00K | 69.00K | 0.00 |
| InterestPaidCFO | -129.00K | -176.00K | -478.00K | -473.00K |
| ChangeInWorkingCapital | 107.51M | -15.16M | -8.43M | 6.84M |
| ChangeInOtherWorkingCapital | 89.48M | -449.00K | -130.00K | 425.00K |
| ChangeInPayablesAndAccruedExpense | 2.35M | 1.91M | -7.19M | 5.13M |
| ChangeInAccruedExpense | 1.37M | 1.14M | -6.11M | 5.21M |
| ChangeInPayable | 977.00K | 770.00K | -1.07M | -84.00K |
| ChangeInPrepaidAssets | 2.13M | -1.75M | -1.72M | 791.00K |
| ChangeInReceivables | 13.55M | -14.87M | 603.00K | 495.00K |
| ChangesInAccountReceivables | 14.80M | -14.80M | 0.00 | 0.00 |
| OtherNonCashItems | 188.00K | 1.10M | -204.00K | -6.20M |
| StockBasedCompensation | 5.47M | 4.37M | 3.33M | 4.13M |
| DepreciationAmortizationDepletion | 2.16M | 2.21M | 2.36M | 2.41M |
| DepreciationAndAmortization | 2.16M | 2.21M | 2.36M | 2.41M |
| Depreciation | 2.16M | 2.21M | 2.36M | 2.41M |
| OperatingGainsLosses | -10.00K | 888.00K | 541.00K | 603.00K |
| PensionAndEmployeeBenefitExpense | -10.00K | 888.00K | 541.00K | 590.00K |
| GainLossOnSaleOfPPE | 0.00 | 0.00 | 13.00K | |
| NetIncomeFromContinuingOperations | -50.92M | -54.23M | -70.75M | -73.00M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for ACIU
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|